A paradigm shift in the way we treat spinal injuries is now in sight, and the world’s first regenerative cell therapy receives the approval of a registration phase I clinical trial. It is a historical milestone that could successfully treat what, until now, has been an incurable condition.
This week, the United States Food and Medicines Administration (FDA) and the National Medical Products Administration (NMPA) approved the global clinical trial to treat spinal cord injury (SCI), which is estimated to affect more than 15 million people worldwide. Sci impacts people throughout demography, and more frequently results from traffic accidents, sports injuries and other traumas, including serious falls and incidents in the workplace. There is no real cure; The treatment is more handling, with surgery and rehabilitation to restore a certain degree of quality of life. However, patients often remain with severe paralysis or disability for life.
Now, the Chinese biotechnology company Xellsmart has the potential to change this forever, since its regenerative therapy of alogenic pluripotent stem cells (IPSC) has received green light by US and Chinese health administrations to enter a clinical trial. Pluripotent stem cells are, of course, immature stem cells that can be developed in specific cells. In this case, the type of replacing damaged or dead neural cells caused by SCI. The treatment aims not only to repair the lesion, but to provide the basis to grow all the necessary cells to return the function to the damaged region.
“Every year, China and the United States report approximately 100,000 and 18,000 new cases of acute or subacute SCI, equivalent to almost 10 and two new cases every hour, respectively,” said an Xellsmart statement. “Most patients experience permanent disability, severely compromising their quality of life. Due to the limited regenerative capacity of the central nervous system, nerve reparation after the LME remains extremely challenging.”
The news of the human essay is carried out from four years of preclinical research and aims to have a broad application that does not require harvesting cells of a patient, but offers a “unique size” treatment that works with anyone who has suffered SCI. This means that, if it happens through the test phases, it will be easy to manufacture and climb for wide access.
And because the subtype of cells that are already well investigated, alogenic cells, from other sources, not native to the patient, should have a low risk of rejection.
The SCI essay is being carried out in association with the third affiliated hospital at the University of Sun Yat-Sen in China, a specialist in the treatment and research of these complex collective injuries.
This trial is the last one for Xellsmart, which is currently testing a specific cell therapy in the treatment of Parkinson’s disease and ELA. If the SCI trial is successful and this new therapy reaches the market, it has a notable potential that includes restoring the function for people with paralysis.
Being realistic, this phase I test, which proves safety and efficacy, as well as dose parameters, must be completed at some time next year, and if it is successful, it will be transferred to the next stage, involving a larger population. It would be expected that phase II will begin in 2028 as very soon. But this therapy could occur in mass and “outside the shelf” available in five to seven years.
“We are moving beyond care and cure,” said an Xellsmart spokesman. “For the first time, we are offering true hope to millions that live with spinal cord injury.”
Source: Xellsmart through PR Newswire
